Intelligence · Clinical Pipeline
Alnylam Netherlands Pipeline
All ClinicalTrials.gov programs at Alnylam Netherlands — phase, modality, and trial IDs.
- Programs
- 29
Quick answer
Alnylam Netherlands has 29 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD
Alnylam Netherlands B.V.
Early-onset Alzheimer's disease (EOAD)
1 trial -
A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease
Alnylam Netherlands B.V.
Alzheimer’s Disease
1 trial -
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Netherlands B.V.
Advanced or Metastatic Hepatocellular Carcinoma
1 trial -
A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease
Alnylam Netherlands B.V.
Huntington’s disease
1 trial -
ALN-4285
Alnylam Netherlands B.V.
Healthy Volunteers
1 trial -
ALN-4915
Alnylam Netherlands B.V.
Healthy Volunteers
1 trial -
ALN-5288
Alnylam Netherlands B.V.
Alzheimer's Disease
1 trial -
ALN-AAT
Alnylam Netherlands B.V.
Antitrypsin Deficiency Liver Disease
1 trial -
ALN-AGT01
Alnylam Netherlands B.V.
Hypertension
1 trial -
ALN-AGT01 RVR
Alnylam Netherlands B.V.
Healthy Volunteers
1 trial -
ALN-APP
Alnylam Netherlands B.V.
Early-Onset Alzheimer Disease
1 trial -
ALN-BCAT
Alnylam Netherlands B.V.
Advanced Hepatocellular Carcinoma
1 trial -
ALN-HBV
Alnylam Netherlands B.V.
Hepatitis B
1 trial -
ALN-HSD
Alnylam Netherlands B.V.
Nonalcoholic Steatohepatitis
1 trial -
ALN-HTT02
Alnylam Netherlands B.V.
Huntington's Disease
1 trial -
ALN-PCS02
Alnylam Netherlands B.V.
Elevated LDL-Cholesterol (LDL-C)
1 trial -
ALN-PCSSC
Alnylam Netherlands B.V.
Hypercholesterolemia
1 trial -
ALN-TTR01
Alnylam Netherlands B.V.
Transthyretin Mediated Amyloidosis (ATTR)
1 trial -
ALN-TTR02
Alnylam Netherlands B.V.
TTR-mediated Amyloidosis
1 trial -
ALN-TTRSC (revusiran)
Alnylam Netherlands B.V.
TTR-mediated Amyloidosis
1 trial -
ALN-TTRSC02
Alnylam Netherlands B.V.
Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
1 trial -
ALN-TTRSC04
Alnylam Netherlands B.V.
Transthyretin-Mediated Amyloidosis
1 trial -
ALN-VSP02
Alnylam Netherlands B.V.
Solid Tumors
2 trials -
Computer algorithm for ATTR
Alnylam Netherlands B.V.
Transthyretin Amyloidosis
1 trial -
Givosiran
Alnylam Netherlands B.V.
Acute Intermittent Porphyria (AIP)
1 trial -
Pozelimab
Alnylam Netherlands B.V.
Healthy
1 trial -
givosiran (ALN-AS1)
Alnylam Netherlands B.V.
Acute Intermittent Porphyria
1 trial -
patisiran
Alnylam Netherlands B.V.
Polyneuropathies
1 trial -
patisiran (ALN-TTR02)
Alnylam Netherlands B.V.
Transthyretin (TTR)-Mediated Amyloidosis
1 trial
Frequently asked questions
How many pipeline programs does Alnylam Netherlands have?
29 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs